The latest price target for iRadimed (NASDAQ:IRMD) was reported by Roth MKM on February 14, 2025. The analyst firm set a price target for $72.00 expecting IRMD to rise to within 12 months (a possible 28.02% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for iRadimed (NASDAQ:IRMD) was provided by Roth MKM, and iRadimed reiterated their buy rating.

There is no last upgrade for iRadimed

There is no last downgrade for iRadimed.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iRadimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iRadimed was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.

While ratings are subjective and will change, the latest iRadimed (IRMD) rating was a reiterated with a price target of $60.00 to $72.00. The current price iRadimed (IRMD) is trading at is $56.24, which is out of the analyst’s predicted range.